Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

被引:704
|
作者
Mattsson, Niklas [1 ,2 ,3 ]
Andreasson, Ulf [4 ,5 ]
Zetterberg, Henrik [4 ,5 ,6 ]
Blennow, Kaj [4 ,5 ]
机构
[1] Lund Univ, Clin Memory Res Unit, Dept Clin Sci, Fac Med, Simrisbanvagen 14, SE-21224 Malmo, Sweden
[2] Skane Univ Hosp, Memory Clin, Scania, Sweden
[3] Skane Univ Hosp, Dept Neurol, Scania, Sweden
[4] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
[5] Univ Gothenburg, Sahlgrenska Acad, Intitute Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden
[6] UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England
基金
美国国家卫生研究院; 加拿大健康研究院; 欧洲研究理事会; 瑞典研究理事会;
关键词
NEUROIMAGING INITIATIVE ADNI; CEREBROSPINAL-FLUID; BIOMARKERS; CHAIN; PROGRESSION; TAU; CSF; DEMENTIA; MARKER; BLOOD;
D O I
10.1001/jamaneurol.2016.6117
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IMPORTANCE Existing cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias. OBJECTIVE To test whether plasma NFL concentrations are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration. DESIGN, SETTING, AND PARTICIPANTS In this prospective case-control study, an ultrasensitive assay was used to measure plasma NFL concentration in 193 cognitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. The study dates were September 7, 2005, to February 13, 2012. The plasma NFL analysis was performed in September 2016. MAIN OUTCOMES AND MEASURES Associationswere tested between plasma NFL and diagnosis, A beta pathologic features, CSF biomarkers of neuronal injury, cognition, brain structure, and metabolism. RESULTS Among 193 cognitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with AD with dementia, plasma NFL correlated with CSF NFL (Spearman rho = 0.59, P < .001). Plasma NFL was increased in patients with MCI (mean, 42.8 ng/L) and patients with AD dementia (mean, 51.0 ng/L) compared with controls (mean, 34.7 ng/L) (P < .001) and had high diagnostic accuracy for patients with AD with dementia vs controls (area under the receiver operating characteristic curve, 0.87, which is comparable to established CSF biomarkers). Plasma NFL was particularly high in patients with MCI and patients with AD dementia with A beta pathologic features. High plasma NFL correlated with poor cognition and AD-related atrophy (at baseline and longitudinally) and with brain hypometabolism (longitudinally). CONCLUSIONS AND RELEVANCE Plasma NFL is associated with AD diagnosis and with cognitive, biochemical, and imaging hallmarks of the disease. This finding implies a potential usefulness for plasma NFL as a noninvasive biomarker in AD.
引用
收藏
页码:557 / 566
页数:10
相关论文
共 50 条
  • [1] Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
    Mattsson, Niklas
    Cullen, Nicholas C.
    Andreasson, Ulf
    Zetterberg, Henrik
    Blennow, Kaj
    JAMA NEUROLOGY, 2019, 76 (07) : 791 - 799
  • [2] Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease
    Ya-Nan Ou
    Hao Hu
    Zuo-Teng Wang
    Wei Xu
    Lan Tan
    Jin-Tai Yu
    Brain Science Advances, 2019, 5 (02) : 94 - 105
  • [3] Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
    Piotr Lewczuk
    Natalia Ermann
    Ulf Andreasson
    Christian Schultheis
    Jana Podhorna
    Philipp Spitzer
    Juan Manuel Maler
    Johannes Kornhuber
    Kaj Blennow
    Henrik Zetterberg
    Alzheimer's Research & Therapy, 10
  • [4] Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease
    Lewczuk, Piotr
    Ermann, Natalia
    Andreasson, Ulf
    Schultheis, Christian
    Podhorna, Jana
    Spitzer, Philipp
    Maler, Juan Manuel
    Kornhuber, Johannes
    Blennow, Kaj
    Zetterberg, Henrik
    ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [5] Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease (vol 76, pg 791, 2019)
    Mattsson, N.
    Cullen, N. C.
    Andreasson, U.
    Zetterberg, H.
    Blennow, K.
    JAMA NEUROLOGY, 2019, 76 (07) : 872 - 872
  • [6] The association of plasma neurofilament light chain and cognitive function in patients with Alzheimer disease and Parkinson disease
    Fuh, Jong-Ling
    Lee, Wei-Ju
    Wang, Shuu-Jiun
    NEUROLOGY, 2018, 90
  • [7] The usefulness of plasma neurofilament light in patients with Alzheimer's disease
    Shim, Yongsoo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 108 - 108
  • [8] Serum neurofilament light in familial Alzheimer disease A marker of early neurodegeneration
    Weston, Philip S. J.
    Poole, Teresa
    Ryan, Natalie S.
    Nair, Akshay
    Liang, Yuying
    Macpherson, Kirsty
    Druyeh, Ronald
    Malone, Ian B.
    Ahsan, R. Laila
    Pemberton, Hugh
    Klimova, Jana
    Mead, Simon
    Blennow, Kaj
    Rossor, Martin N.
    Schott, Jonathan M.
    Zetterberg, Henrik
    Fox, Nick C.
    NEUROLOGY, 2017, 89 (21) : 2167 - 2175
  • [9] The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease
    Jung, Youjin
    Damoiseaux, Jessica S.
    BRAIN, 2024, 147 (01) : 12 - 25
  • [10] SCREENING FOR NEURODEGENERATION IN LCH WITH NEUROFILAMENT LIGHT IN PLASMA
    Henter, Jan-Inge
    Sveijer, Malin
    Jadersten, Martin
    Kvedaraite, Egle
    Zetterberg, Henrik
    Blennow, Kaj
    Lourda, Magda
    Gavhed, Desiree
    Greenwood, Tatiana von Bahr
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S20 - S21